In this study, we compared blast clearance dynamics and remission outcomes among intensively treated patients with AML with IDH2 R140 and IDH2 R172 mutations, and further between IDH1 and IDH2 mutations in a single‐center AML cohort. The gene discussed is IDH2; the disease is acute myeloid leukemia.